Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sarcoidosis, Pulmonary Clear all
Completed Not applicable Interventional

Diagnostic Yield of Intranodal Forceps Biopsies in Mediastinal Adenopathy

NCT05374447
View directory record Official record
Conditions
Mediastinal Lymphadenopathy, Sarcoidosis, Pulmonary, Mediastinal Diseases
Interventions
Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy
Procedure
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 99 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jun 10, 2026, 2:13 PM EDT
Terminated Phase 1 Interventional

Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis

NCT01440192
View directory record Official record
Conditions
Stage 2 Pulmonary Sarcoidosis, Stage 3 Pulmonary Sarcoidosis
Interventions
PDA001 (cenplacel-L)
Biological
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Birmingham, Alabama • Denver, Colorado • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Jun 10, 2026, 2:13 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

University of Virginia Natural History Study

NCT04896138
View directory record Official record
Conditions
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Diseases, Hypersensitivity Pneumonitis, Idiopathic Interstitial Pneumonias
Interventions
Interstitial Lung Disease
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2035
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

NCT04064242
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
CMK389, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Birmingham, Alabama • Gainesville, Florida • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Jun 10, 2026, 2:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Lung Microbiome in Sarcoidosis

NCT02520323
View directory record Official record
Conditions
Sarcoidosis
Interventions
Blood draw, Bronchoscopy, Questionnaires
Other · Procedure · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Jun 10, 2026, 2:13 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis

NCT05314517
View directory record Official record
Conditions
Sarcoidosis, Pulmonary
Interventions
Namilumab, Placebo
Drug
Lead sponsor
Kinevant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
24
States / cities
Birmingham, Alabama • Palo Alto, California • Valencia, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Jun 10, 2026, 2:13 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Role of Genetic Factors in the Development of Lung Disease

NCT00001532
View directory record Official record
Conditions
Cystic Fibrosis, Pulmonary Fibrosis, Tuberous Sclerosis, Asthma, Pulmonary Sarcoidosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 90 Years
Enrollment
3,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1996
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Phase 2Phase 3 Interventional

Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension

NCT00581607
View directory record Official record
Conditions
Sarcoidosis, Pulmonary Arterial Hypertension
Interventions
Bosentan, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
New York, New York • Cincinnati, Ohio • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Not applicable Interventional

A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis

NCT03324503
View directory record Official record
Conditions
Sarcoidosis, Pulmonary
Interventions
Glucocorticoid (prednisone or prednisolone)
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
Birmingham, Alabama • Iowa City, Iowa • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Phase 2 Interventional

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

NCT03814317
View directory record Official record
Conditions
Sarcoidosis, Precapillary Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Inhaled Treprostinil
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jun 10, 2026, 2:13 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

NCT00470327
View directory record Official record
Conditions
Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Disorder
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jun 10, 2026, 2:13 PM EDT
Terminated Phase 4 Interventional Results available

Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")

NCT00747461
View directory record Official record
Conditions
Lung Diseases, Obstructive, Sarcoidosis, Wegener's Granulomatosis, Rhinoscleroma, Recurrent Respiratory Papillomatosis
Interventions
CryoSpray Ablation
Device
Lead sponsor
CSA Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Not applicable Interventional Results available

Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability

NCT01615484
View directory record Official record
Conditions
Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
Interventions
Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™, STEEN Solution™
Procedure · Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Jun 10, 2026, 2:13 PM EDT
Not yet recruiting No phase listed Observational

A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension

NCT07613216
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung, Pulmonary Hypertension, Usual Interstitial Pneumonia
Interventions
Not listed
Lead sponsor
Cosmos Rx, Inc
Industry
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

Atorvastatin to Treat Pulmonary Sarcoidosis

NCT00279708
View directory record Official record
Conditions
Sarcoidosis, Pulmonary
Interventions
Atorvastatin, Placebo Oral Tablet
Drug · Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Jun 10, 2026, 2:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune Response to SARS-CoV-2/COVID-19 Vaccination in Sarcoidosis

NCT05089565
View directory record Official record
Conditions
Sarcoidosis, SARS-CoV2 Infection, Vaccine Response Impaired
Interventions
Assay of (1) the level of anti-spike IgG antibody, and (2) interferon-gamma release in response to SARS-CoV-2 antigen stimulation
Diagnostic Test
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Jun 10, 2026, 2:13 PM EDT
Not listed No phase listed Observational

Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis

NCT03145922
View directory record Official record
Conditions
Sarcoidosis, Sarcoidosis, Pulmonary
Interventions
Observational Study
Other
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Jun 10, 2026, 2:13 PM EDT
Not listed Phase 4 Interventional

Pirfenidone for Progressive Fibrotic Sarcoidosis

NCT03260556
View directory record Official record
Conditions
Sarcoidosis, Pulmonary
Interventions
Pirfenidone, Placebos
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Jun 10, 2026, 2:13 PM EDT
Completed No phase listed Observational

Identifying Shared Genetic Susceptibility Regions in Chronic Beryllium Disease and Sarcoidosis

NCT00560989
View directory record Official record
Conditions
Sarcoidosis, Berylliosis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis

NCT03824392
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
Efzofitimod 1.0 mg/kg or Placebo, Efzofitimod 3.0 mg/kg or Placebo, Efzofitimod 5.0 mg/kg or Placebo
Biological
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Northridge, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Jun 10, 2026, 2:13 PM EDT
Not listed No phase listed Observational

Use of Immunosuppressive Therapy for Sarcoidosis

NCT02356445
View directory record Official record
Conditions
Sarcoidosis
Interventions
Cytotoxic drug
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
15 Years to 90 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Results available

Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis

NCT03793439
View directory record Official record
Conditions
Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis
Interventions
Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial, Spirometry, RNA Sequencing, Laboratory testing, Corticosteroid, Tofacitinib 5mg [Xeljanz] 1 year open-label extension
Drug · Diagnostic Test · Genetic
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Not applicable Interventional Results available

The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis

NCT01587001
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
N-acetyl-cysteine, Placebo
Dietary Supplement · Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Phase 2 Interventional

A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis

NCT03727451
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Fibrosis, Sarcoidosis, Pulmonary
Interventions
iNO
Combination Product
Lead sponsor
Bellerophon
Industry
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Miami, Florida • Cincinnati, Ohio • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Jun 10, 2026, 2:13 PM EDT